For instance, enhanced TRIM31 expression could be a positive biomarker for poor clinical outcomes, and TRIM31 confers gemcitabine resistance in pancreatic carcinoma cells by activating the NF-κB pathway14. This evidence concerns the gene TRIM31 and exocrine pancreatic carcinoma.